Director at Avalo Therapeutics (NASDAQ: AVTX) receives 1,339 options

Rhea-AI Filing Summary

Avalo Therapeutics director Rita Jain received a new stock option grant. On March 31, 2026, she was granted options to acquire 1,339 shares of Avalo Therapeutics common stock at an exercise price of $14.93 per share. The options were granted fully vested and expire on March 31, 2036. Following this grant, she holds 1,339 options directly as reported in this filing.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jain Rita

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,339	$12.13	$16K

Holdings After Transaction: Stock Option (Right to Buy) — 1,339 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 1,339 options Exercise price: $14.93 per share Grant date value reference: $12.13 per option +2 more

5 metrics

Options granted 1,339 options Director grant on March 31, 2026

Exercise price $14.93 per share Stock option strike price for common stock

Grant date value reference $12.13 per option Reported transaction price per option at grant

Total options held after grant 1,339 options Total derivative holdings following this transaction

Option expiration March 31, 2036 Expiration date of granted stock options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, derivative

4 terms

Stock Option (Right to Buy) financial

"Security title listed as "Stock Option (Right to Buy)" for the grant."

Grant, award, or other acquisition financial

"Transaction code description states "Grant, award, or other acquisition"."

Common Stock financial

"Underlying security title for the option is shown as "Common Stock"."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

derivative financial

"Transaction type is categorized as "derivative" in the data."

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.93	03/31/2026		A		1,339		(1)	03/31/2036	Common Stock	1,339	$12.13	1,339	D

Explanation of Responses:

1. The options were granted on March 31, 2026, and are 100% vested.

	/s/ Christopher Sullivan, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Avalo Therapeutics (AVTX) report for Rita Jain?

Avalo Therapeutics (AVTX) reported that director Rita Jain received a grant of 1,339 stock options on March 31, 2026. These options give her the right to buy common shares at a preset price as part of her compensation package.

What is the exercise price of Rita Jain’s new AVTX stock options?

The granted options allow director Rita Jain to buy Avalo Therapeutics (AVTX) common stock at an exercise price of $14.93 per share. This strike price is fixed for the life of the option, regardless of future market price movements.

How many Avalo Therapeutics (AVTX) options does Rita Jain hold after this filing?

After the reported grant, director Rita Jain holds 1,339 stock options in Avalo Therapeutics (AVTX). The filing shows this full amount as her direct derivative holdings following the transaction, reflecting only this single option award.

When do Rita Jain’s Avalo Therapeutics (AVTX) stock options expire?

The stock options granted to director Rita Jain in Avalo Therapeutics (AVTX) expire on March 31, 2036. She can choose to exercise them any time before this expiration date, subject to the option terms and her own decisions.

Are Rita Jain’s new AVTX stock options already vested?

Yes. The footnote explains that Rita Jain’s Avalo Therapeutics (AVTX) options granted on March 31, 2026 are 100% vested. This means she has the immediate right to exercise them, rather than waiting for a vesting schedule to complete.